Applied Genetic Technologies (AGTC) Prices 6.5M Share Common Offering at $5/Sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Applied Genetic Technologies (AGTC) Prices 6.5M Share Common Offering at $5/Sh

Applied Genetic Technologies Corp. (AGTC) PT Raised to $10 at Chardan Capital Markets

February 6, 2020 12:10 PM EST

Chardan Capital Markets analyst Gbola Amusa raised the price target on Applied Genetic Technologies Corp. (NASDAQ: AGTC) to $10.00 (from $7.50) while maintaining a Buy rating.

... More

Pre-Open Stock Movers 02/06: (UIS) (FSCT) (LDOS) Higher (TNXP) (RWLK) (FNKO) Lower (more...)

February 6, 2020 9:24 AM EST

Pre-Open Stock Movers

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) 56.5% LOWER; announced today that the Company has decided to stop enrollment in the Phase 3 RECOVERY study of Tonmya# or TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD) following an unblinded, pre-specified interim analysis by the Independent Data Monitoring Committee (IDMC). Based on interim analysis results of the first 50% of enrolled participants, the IDMC recommended stopping the trial for futility as Tonmya is unlikely to demonstrate a statistically significant improvement in the... More

After-Hours Stock Movers 02/05: (SONO) (ELF) (ZNGA) Higher; (TNXP) (FNKO) (GPRO) Lower (more...)

February 5, 2020 6:00 PM EST

After-Hours Movers

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) 64.7% LOWER; announced today that the Company has decided to stop enrollment in the Phase 3 RECOVERY study of Tonmya# or TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD) following an unblinded, pre-specified interim analysis by the Independent Data Monitoring Committee (IDMC). Based on interim analysis results of the first 50% of enrolled participants, the IDMC recommended stopping the trial for futility as Tonmya is unlikely to demonstrate a statistically significant improvement in the primary... More

Applied Genetic Technologies (AGTC) Announces Proposed 6M Share Public Offering of Common Stock

February 5, 2020 4:37 PM EST

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All the shares in the offering will be sold by AGTC. In addition, AGTC expects to grant the underwriters a 30-day option to purchase up to... More